All In Biotech

Drug Trial Radar · NCT06434610

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 11, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

Conditions

  • Platinum-resistant Recurrent Ovarian Cancer

Interventions

  • B013Drug

    B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

  • PaclitaxelDrug

    Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.

  • PlaceboDrug

    Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Approximately 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China · Recruiting

  • XiangYa Hospital CentralSouth University

    Changsha, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, China · Recruiting

  • Fudan University Shanghai Cancer center

    Shanghai, China · Recruiting

  • The Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China · Recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Shananxi Provincial Cancer Hospital

    Xi'an, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Recruiting

  • Yibin city second people's Hospital

    Yibin, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.